Actinium Pharmaceuticals (STU:7AY1) 3-Year Book Growth Rate : -27.80% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals 3-Year Book Growth Rate?

Actinium Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €1.37.

During the past 12 months, Actinium Pharmaceuticals's average Book Value per Share Growth Rate was -32.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was -27.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Actinium Pharmaceuticals was 110.40% per year. The lowest was -95.50% per year. And the median was -7.60% per year.

Competitive Comparison of Actinium Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Actinium Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinium Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's 3-Year Book Growth Rate falls into.

Actinium Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Actinium Pharmaceuticals (STU:7AY1) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Actinium Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals (STU:7AY1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ATNM:USA 7AY1:Germany

Address

275 Madison Avenue, 7th Floor, New York, NY, USA, 10016

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals (STU:7AY1) Headlines

No Headlines